Plans call for Epax to increase capacity at its central manufacturing facility in Ålesund and production is expected to increase by over 50% by 2021.
“This substantial investment will open up new opportunities for the marine ingredients sector in terms of concentration, purity and quality,” said Bjørn Refsum, CEO of Epax.
“We are particularly excited about our new distillation process, which we believe is the most effective and environmentally friendly way to achieve high levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) without creating unwanted by-products and waste.” .
Epax can look back on a long history of innovation in the omega-3 sector and invented the technology for concentrating fish oil as an ethyl ester back in 1987.
The company’s investments in innovation continue to this day, as details of a new distillation process were revealed back in May that can achieve concentrations of up to 70% by weight (compared to the current industry standard of 50%).
“The mild nature of the next generation distillation process makes it a highly effective way to increase EPA and DHA levels without creating unwanted by-products like trans fats and polymers,” the company said.
Epax recently spoke about its efforts to reduce production waste and create a green company.
“One of our priorities is to reduce local truck traffic and the air pollution from this traffic. We have now achieved a dramatic reduction in road traffic by moving the majority of our by-product shipments to sea and building up the production of our own biofuel. “
Part of the investment will be used to build a new manufacturing facility nearby that will provide raw materials for new and specialized marine ingredients.
“Our biofuel is made from the by-products of our omega-3 production and burns extremely cleanly, with very little dust generated when burned,” said Epax. “And of course it comes from renewable sources.”
Encouraging results .
The company’s omega-3 oils were the subject of a recent to studyWhose supplementation was strongly linked to increased neural blood flow.
This increase in blood volume could potentially prevent memory loss caused by decreased blood flow or inflammation of the brain cells.
“DHA is the most abundant omega-3 fatty acid in the brain and has a number of important effects that prevent inflammatory cell death in the brain. This is the pathological basis for Alzheimer’s disease,” said Dr. Morten Bryhn, Scientific Advisor at Epax.
“EPA is another marine omega-3 fatty acid that is lower in the brain, although it is fortified with arterial endothelium, which is responsible for maintaining arterial tone and blood flow.”
Epax has been a wholly owned subsidiary of the Norwegian company Pelagia since August 2017. Prior to that, the company was bought and subsequently sold by specialty chemicals company FMC Corporation. FMC paid € 312 million for Epax in 2013.